bioAffinity Releases New Case Study on Lung Cancer Diagnosis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 19 2026
0mins
Should l Buy BIAF?
bioAffinity Technologies released a new clinical case study in which its CyPath Lung noninvasive diagnostic test for lung cancer helped determine the appropriate treatment for a 79-year-old female with a suspicious lung finding on a low-dose computed tomography scan. The patient, a current smoker with a medical history significant for chronic obstructive pulmonary disease and coronary heart disease, underwent LDCT screening in June 2025. Imaging revealed a spiculated, or irregularly shaped, nodule about half an inch in size at the bottom of the right lung, near the lining of the lung. Spiculated nodules raise concerns about malignancy due to their uneven, irregular appearance. The CyPath Lung test result was negative, indicating an unlikely malignancy in the lung and supporting a conservative management approach that includes annual CT screening. A repeat scan in October 2025 showed that the suspicious finding from the June scan had resolved, and there were no pulmonary nodules in the lungs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BIAF?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BIAF
About BIAF
bioAffinity Technologies, Inc. is a biotechnology company focused on the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. It develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
bioAffinity Technologies 2025 Financial Overview
- Financial Performance: bioAffinity Technologies reported a FY GAAP EPS of -$8.66 with revenues of $6.2 million, indicating challenges in revenue growth and reflecting pressure in market competition.
- Operating Expense Reduction: Operating expenses decreased by 9% to $16.7 million in 2025, primarily due to strategic actions aimed at streamlining and reducing lab operation costs, which alleviated some financial pressure.
- R&D Investment: Research and development expenses were $1.4 million in 2025, slightly lower than the prior year, demonstrating the company's commitment to ongoing investment in lab operations and preclinical development despite financial losses.
- Cash Flow Status: As of December 31, 2025, cash and cash equivalents were $6.5 million, a significant increase from $1.1 million at the end of 2024, primarily due to $16.9 million raised in multiple financings in 2025 to support ongoing operations.
See More
bioAffinity Technologies Stock Soars on Strong CyPath Lung Results
- CyPath Lung Revenue Surge: bioAffinity reported an 87% year-over-year increase in CyPath Lung revenue for 2025, with test volumes soaring by 99%, indicating a 67% rise in orders from physician offices and clinics, reflecting enhanced market awareness and positive clinical experiences.
- Widening Net Loss: Despite revenue growth, bioAffinity's net loss widened from $9 million to $14.9 million, primarily due to changes in the fair value of warrants, expanded sales activities, and increased clinical development spending, highlighting financial pressures during the company's strategic shift.
- Improved Cash Flow: The company's cash and cash equivalents improved to $6.5 million at year-end, up from $1.1 million last year, bolstered by approximately $16.9 million raised in 2025 financings, enhancing its financial foundation for future business expansion.
- Optimistic Future Outlook: bioAffinity expects CyPath Lung unit sales to increase by over 100% in 2026, indicating that its efforts in commercialization and clinical validation are likely to drive future revenue growth and further solidify its market position.
See More
bioAffinity Technologies Shares Surge 72% on Lung Cancer Study Announcement
- Clinical Study Launch: bioAffinity Technologies has announced the initiation of a major longitudinal clinical study evaluating the noninvasive CyPath Lung diagnostic, which will follow up to 2,000 high-risk patients across 17 medical centers, aiming to validate the test's sensitivity and specificity for early lung cancer detection, thereby enhancing the company's competitive edge in the lung cancer screening market.
- Revenue Changes: In 2025, bioAffinity reported revenue of $6.2 million, down from $9.4 million in 2024, reflecting the company's strategic decision to discontinue unprofitable pathology services and focus on the high-value CyPath Lung test, although testing revenue for CyPath Lung increased by 87% year-over-year, indicating strong market demand.
- Financial Status: The company recorded a net loss of $14.9 million in 2025, compared to a loss of $9.0 million in 2024, primarily due to changes in warrant valuations and expanded clinical development activities; however, it ended the year with $6.5 million in cash and cash equivalents, demonstrating some financial resilience.
- Future Outlook: bioAffinity expects unit sales of CyPath Lung to more than double in 2026, supported by growing physician adoption, expansion into new markets, and broader integration into federal healthcare systems, further solidifying its growth potential in the lung cancer screening market.
See More
U.S. Stocks Rise in Morning Trade Amid Economic Slowdown
- Dow Jones Surge: The Dow Jones Industrial Average gained over 300 points on Friday, rising 0.68% to 46,995.67, indicating a positive market reaction to economic data that may boost investor confidence.
- NASDAQ and S&P 500 Performance: The NASDAQ rose 0.40% to 22,401.88, while the S&P 500 increased by 0.50% to 6,706.16, reflecting strong performances in tech and large-cap stocks, suggesting optimism about future growth.
- Economic Growth Slowdown: According to the Bureau of Economic Analysis, the GDP growth rate for Q4 2025 was revised down to 0.7% from an initial estimate of 1.4%, marking a sharp deceleration from the 4.4% growth pace in Q3, highlighting concerns about economic momentum.
- Commodity Market Fluctuations: Oil prices fell by 1.7% to $94.11, and gold dipped 0.2% to $5,118.00 on Friday, indicating that uncertainties about the economic outlook are impacting commodity prices, potentially leading investors to reassess risks.
See More
bioAffinity Technologies Reports 2025 Financial Highlights
- CyPath® Lung Test Surge: In 2025, the number of CyPath® Lung tests performed increased by 99% compared to 2024, reflecting enhanced clinical utilization and rising market demand, which is expected to further drive the company's expansion in the lung cancer diagnostics market.
- Revenue and Expense Dynamics: While total revenue decreased by 34% from 2024, revenue from CyPath® Lung surged by 87%, demonstrating the success of the company's strategic shift towards high-value diagnostic services, alongside a 9% reduction in operating expenses that optimized the cost structure.
- Expanded Physician Network: The number of physicians and clinics ordering CyPath® Lung tests rose by 67% year-over-year in 2025, with this trend expected to accelerate in 2026, further strengthening the company's competitive position in the market.
- Financing and Innovation Progress: The company raised approximately $16.9 million in gross proceeds through equity transactions in 2025 to support the clinical development and commercialization of CyPath® Lung, while also making advancements in diagnostic tests for chronic obstructive pulmonary disease and asthma.
See More
BIOAFFINITY TECHNOLOGIES REPORTS RECORD REVENUE AND UNIT SALES FOR CYPATH® LUNG, ITS LEADING LUNG CANCER DIAGNOSTIC, IN 2025
Record Revenue Announcement: BioAffinity Technologies has announced record revenue for 2025, indicating strong financial performance.
Unit Sales Growth: The company reported significant unit sales for its flagship product, the Lung Cancer Diagnostic CyPath®, highlighting its market success.
See More
bioAffinity Technologies 2025 Financial Overview
- Financial Performance: bioAffinity Technologies reported a FY GAAP EPS of -$8.66 with revenues of $6.2 million, indicating challenges in revenue growth and reflecting pressure in market competition.
- Operating Expense Reduction: Operating expenses decreased by 9% to $16.7 million in 2025, primarily due to strategic actions aimed at streamlining and reducing lab operation costs, which alleviated some financial pressure.
- R&D Investment: Research and development expenses were $1.4 million in 2025, slightly lower than the prior year, demonstrating the company's commitment to ongoing investment in lab operations and preclinical development despite financial losses.
- Cash Flow Status: As of December 31, 2025, cash and cash equivalents were $6.5 million, a significant increase from $1.1 million at the end of 2024, primarily due to $16.9 million raised in multiple financings in 2025 to support ongoing operations.
See More
bioAffinity Technologies Stock Soars on Strong CyPath Lung Results
- CyPath Lung Revenue Surge: bioAffinity reported an 87% year-over-year increase in CyPath Lung revenue for 2025, with test volumes soaring by 99%, indicating a 67% rise in orders from physician offices and clinics, reflecting enhanced market awareness and positive clinical experiences.
- Widening Net Loss: Despite revenue growth, bioAffinity's net loss widened from $9 million to $14.9 million, primarily due to changes in the fair value of warrants, expanded sales activities, and increased clinical development spending, highlighting financial pressures during the company's strategic shift.
- Improved Cash Flow: The company's cash and cash equivalents improved to $6.5 million at year-end, up from $1.1 million last year, bolstered by approximately $16.9 million raised in 2025 financings, enhancing its financial foundation for future business expansion.
- Optimistic Future Outlook: bioAffinity expects CyPath Lung unit sales to increase by over 100% in 2026, indicating that its efforts in commercialization and clinical validation are likely to drive future revenue growth and further solidify its market position.
See More
bioAffinity Technologies Shares Surge 72% on Lung Cancer Study Announcement
- Clinical Study Launch: bioAffinity Technologies has announced the initiation of a major longitudinal clinical study evaluating the noninvasive CyPath Lung diagnostic, which will follow up to 2,000 high-risk patients across 17 medical centers, aiming to validate the test's sensitivity and specificity for early lung cancer detection, thereby enhancing the company's competitive edge in the lung cancer screening market.
- Revenue Changes: In 2025, bioAffinity reported revenue of $6.2 million, down from $9.4 million in 2024, reflecting the company's strategic decision to discontinue unprofitable pathology services and focus on the high-value CyPath Lung test, although testing revenue for CyPath Lung increased by 87% year-over-year, indicating strong market demand.
- Financial Status: The company recorded a net loss of $14.9 million in 2025, compared to a loss of $9.0 million in 2024, primarily due to changes in warrant valuations and expanded clinical development activities; however, it ended the year with $6.5 million in cash and cash equivalents, demonstrating some financial resilience.
- Future Outlook: bioAffinity expects unit sales of CyPath Lung to more than double in 2026, supported by growing physician adoption, expansion into new markets, and broader integration into federal healthcare systems, further solidifying its growth potential in the lung cancer screening market.
See More
U.S. Stocks Rise in Morning Trade Amid Economic Slowdown
- Dow Jones Surge: The Dow Jones Industrial Average gained over 300 points on Friday, rising 0.68% to 46,995.67, indicating a positive market reaction to economic data that may boost investor confidence.
- NASDAQ and S&P 500 Performance: The NASDAQ rose 0.40% to 22,401.88, while the S&P 500 increased by 0.50% to 6,706.16, reflecting strong performances in tech and large-cap stocks, suggesting optimism about future growth.
- Economic Growth Slowdown: According to the Bureau of Economic Analysis, the GDP growth rate for Q4 2025 was revised down to 0.7% from an initial estimate of 1.4%, marking a sharp deceleration from the 4.4% growth pace in Q3, highlighting concerns about economic momentum.
- Commodity Market Fluctuations: Oil prices fell by 1.7% to $94.11, and gold dipped 0.2% to $5,118.00 on Friday, indicating that uncertainties about the economic outlook are impacting commodity prices, potentially leading investors to reassess risks.
See More
bioAffinity Technologies Reports 2025 Financial Highlights
- CyPath® Lung Test Surge: In 2025, the number of CyPath® Lung tests performed increased by 99% compared to 2024, reflecting enhanced clinical utilization and rising market demand, which is expected to further drive the company's expansion in the lung cancer diagnostics market.
- Revenue and Expense Dynamics: While total revenue decreased by 34% from 2024, revenue from CyPath® Lung surged by 87%, demonstrating the success of the company's strategic shift towards high-value diagnostic services, alongside a 9% reduction in operating expenses that optimized the cost structure.
- Expanded Physician Network: The number of physicians and clinics ordering CyPath® Lung tests rose by 67% year-over-year in 2025, with this trend expected to accelerate in 2026, further strengthening the company's competitive position in the market.
- Financing and Innovation Progress: The company raised approximately $16.9 million in gross proceeds through equity transactions in 2025 to support the clinical development and commercialization of CyPath® Lung, while also making advancements in diagnostic tests for chronic obstructive pulmonary disease and asthma.
See More
BIOAFFINITY TECHNOLOGIES REPORTS RECORD REVENUE AND UNIT SALES FOR CYPATH® LUNG, ITS LEADING LUNG CANCER DIAGNOSTIC, IN 2025
Record Revenue Announcement: BioAffinity Technologies has announced record revenue for 2025, indicating strong financial performance.
Unit Sales Growth: The company reported significant unit sales for its flagship product, the Lung Cancer Diagnostic CyPath®, highlighting its market success.
See More
